Skip to main content

Articles

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer

FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma

FDA Approvals, Urothelial Cancer, Oncology

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

In the News, Practice Management

CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak

Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma

Multiple Myeloma, Oncology

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Phoebe Starr

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Chase Doyle

Leukemia, Oncology

Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia

Chase Doyle

Leukemia, Oncology

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Wayne Kuznar

Page 38 of 244
Results 371 - 380 of 2440